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Abstract
Background: The rapid diagnostic tests for malaria (RDT) constitute a fast and opportune alternative for non-
complicated malaria diagnosis in areas where microscopy is not available. The objective of this study was to validate a 
RDT named Parascreen™ under field conditions in Iquitos, department of Loreto, Peru. Parascreen™ is a RDT that detects 
the histidine-rich protein 2 (HRP2) antigen from Plasmodium falciparum and lactate deshydrogenase from all 
Plasmodium species.
Methods: Parascreen™ was compared with microscopy performed by experts (EM) and polymerase chain reaction 
(PCR) using the following indicators: sensitivity (Se), specificity (Sp), positive (PV+) and negative predictive values (PV-), 
positive (LR+) and negative likehood ratio (LR-).
Results: 332 patients with suspected non-complicated malaria who attended to the MOH health centres were 
enrolled between October and December 2006. For P. falciparum malaria, Parascreen™ in comparison with EM, had Se: 
53.5%, Sp: 98.7%, PV+: 66.7%, PV-: 97.8%, LR+: 42.27 and LR-: 0.47; and for non-P. falciparum malaria, Se: 77.1%, Sp: 97.6%, 
PV+: 91.4%, PV-: 92.7%, LR+: 32.0 and LR-: 0.22. The comparison of Parascreen™ with PCR showed, for P. falciparum 
malaria, Se: 81.8%, Sp: 99.1%, PV+: 75%, PV-: 99.4, LR+: 87.27 and LR-: 0.18; and for non-P. falciparum malaria Se: 76.1%, 
Sp: 99.2%, PV+: 97.1%, PV-: 92.0%, LR+: 92.51 and LR-: 0.24.
Conclusions: The study results indicate that Parascreen™ is not a valid and acceptable test for malaria diagnosis under 
the field conditions found in the Peruvian Amazon. The relative proportion of Plasmodium species, in addition to the 
genetic characteristics of the parasites in the area, must be considered before applying any RDT, especially after the 
finding of P. falciparum malaria parasites lacking pfhrp2 gene in this region.
Background
Malaria affects people in more than 108 countries around
the world, with nearly 243 million estimated cases and
nearly 863 thousands of deaths reported in the last year
[1]. Despite a reduction of the incidence by up to 40%
during the last four years in Peru, malaria due to Plasmo-
dium falciparum and  Plasmodium vivax remains an
important public health problem, especially in the Ama-
zon region where more than 70% of the cases of the coun-
try are reported [2].
In malaria patients, a prompt and accurate diagnosis is
the key for effective disease management, in order to
reduce the probability of complications and mortality.
The two diagnostic approaches currently in use, clinical
diagnosis and microscopy, do not allow a satisfactory
diagnosis of malaria. Clinical diagnosis, the most widely
used, is unreliable because the symptoms of malaria are
non-specific [3,4]. Diagnosis by microscopy, the estab-
lished method for laboratory confirmation of malaria,
presents technical and personnel requirements that often
cannot be achieved [4-8], particularly in many areas of
the Amazon region, far away from the main cities, where
the population is widely dispersed and few health centres
exist. Because of the reasons mentioned above and with
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the appearance of severe vivax malaria cases in different
countries around the world in the last years [9], it is
imperative to have a rapid and appropriate diagnosis
method for malaria in Peru.
Rapid diagnostic tests for malaria (RDT) offer a good
alternative with the advantage that it is an easy and rapid
method, which requires minimum training [6,7,10-12].
The evaluation of different RDTs in many places in the
last decade has demonstrated high sensitivity and speci-
ficity, compared with expert microscopy diagnosis as gold
standard [3,6,8,10,11,13-15]. However, it was also
observed that the same RDT used in different places
showed different results, which is probably related to dif-
ferent conditions found in these places (temperature,
humidity, characteristics of the malaria parasites, etc.).
This is one of the reasons why initiatives like the WHO/
TDR/FIND malaria RDT product testing programme,
evaluating different RDTs under standardized conditions;
could guide the malaria programmes in different coun-
tries to select the best RDT for a specific region [16].
Furthermore, the recent finding of P. falciparum field
isolates lacking expression of the pfhrp2 gene in the Peru-
vian Amazon region should also be taken into account to
choose the proper RDT for this region [17].
For more sensitive malaria detection, several poly-
merase chain reaction (PCR) assays have also been devel-
oped, and are mainly used in epidemiological studies [18].
The major advantage of this approach is the capability to
detect malaria parasites in patients with low levels of par-
asitaemia, (five or less parasites per μL of blood), includ-
ing sub-patent malaria infections, which can be detected
with 100% of sensitivity and specificity. However, the dif-
ficulty in acquiring and maintaining the required techni-
c a l  s k i l l s  i s  t h e  m a i n  d i s a d v a n t a g e  o f  t h i s  t e c h n i q u e
[7,8,14].
Parascreen™ is a RDT that has been assessed in differ-
ent studies in Asian and African countries [19-21], where
the test performed well under field conditions. In the
present study Parascreen™ was evaluated in different
communities around Iquitos, department of Loreto, Peru,
and compared its performance with expert microscopy
and PCR.
Methods
Study design and specimens
Patients with history of fever with or without chills,
sweating and headache (clinical symptoms suspicious of
malaria), and with no history of anti-malarial treatment
during the last two weeks, were enrolled through a pas-
sive malaria case detection in six health facilities around
Iquitos (Department of Loreto) in the Peruvian Amazon,
between October and December 2006. The minimum
required sample size for this study was determined to be
96 confirmed malaria cases and 96 non-malaria cases,
assuming a sensitivity and specificity at 90% with a preci-
sion of 6%, at a 95% confidence interval.
Blood samples for thick and thin blood films, for the
Parascreen™ test and for PCR (collected on filter paper, 3
MM), were collected by finger-prick. Diagnosis proce-
dures, including microscopy, Parascreen™ and PCR, were
carried out by different staff blinded to each other result.
Expert microscopy
This procedure was carried out in the six health centres,
located in rural areas, using standard protocols according
to the Peruvian national guidelines [22]. Thick smears
prepared with a finger-prick sample were stained with
10% Giemsa and examined using a microscope with a 100
× oil immersion objective. The parasite density was
expressed as the number of parasites/μl of blood, by using
an average number of leucocytes per microlitre of blood
of 6,000 (according to the Peruvian national guidelines)
for the calculations (number of counted parasites, multi-
plied by 6,000, divided by the number of counted leuco-
cytes, by counting a total of ≥200 and ≥500 leucocytes if
the number of parasites per microscope field is > 10 and <
10, respectively) [22]. The results were recorded together
with clinical and epidemiological data from each patient.
For the quality control, 10% of the slides were examined
by a second expert microscopist at the reference labora-
tory (Centro de Salud San Juan) in Iquitos.
Parascreen™
Parascreen™(Zephyr Biomedical Systems, lot: 101051) is a
RDT that detects the histidine-rich protein 2 antigen of P.
falciparum  and the lactate deshydrogenase of Plasmo-
dium. The reactive strip has three different detection
lines: a distal line with non-specific antibodies that recog-
nize HRP-2 P. falciparum; a middle line with specific anti-
bodies that recognize the lactate deshydrogenase enzyme
of the "pan malaria group" (P. falciparum and non -P. fal-
ciparum), and a proximal line with antibodies that cap-
ture the excess of conjugate and therefore function as an
assay control.
The RDT was performed and results were interpreted
according to the manufacturer's instructions [23]. Briefly,
only one pink-purple line in the proximal area (control
line) means negative for malaria; one pink-purple line in
the middle area, in addition to the control line, means
non-P. falciparum infection; one pink-purple line, in
addition to the previous two bands, means P. falciparum
infection. When the control line did not appear or the
interpretation was doubtful, the test was repeated.
PCR procedures
The parasite DNA was extracted from the filter paper
using the Chelex - 100 method (Bio-Rad Laboratories,
Hercules, CA). Filter paper blood spots prepared with
approximately 20 μL of blood were cut into pieces ofBendezu et al. Malaria Journal 2010, 9:154
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approximately 5 mm2, and incubated with 20 μL of 0.05%
saponin (Sigma™) at room temperature for four hours.
Then 10 μL of 20% Chelex - 100 solution was added, and
the sample was incubated for 10 minutes at 95°C, fol-
lowed by a centrifugation at 11,000 g. The supernatant
(DNA) was transferred into a new tube and stored at -
20°C until use. The DNA was amplified by a semi-nested
multiplex PCR method, as described by Rubio et al [24],
The PCR products were analyzed in a 2% agarose gel
(analytic grade, Promega™) with a 100 pb DNA marker
(Promega™), using ethidium bromide staining (0.5 μg/ml)
and a data image Analyzer with UV trans-illuminator
(Gel Doc option, BioRad™).
Data analysis
All quantitative data were encoded in a data sheet and
processed using SPSS 12.0 for Windows and XLSTAT
2007. A 2 × 2 table was created to analyze association val-
ues between the three diagnosis methods. The following
indicators for Parascreen™ RDT detection were calcu-
lated, using either PCR or expert microscopy (EM) as the
gold standard: (95% CI): sensitivity (Se), specificity (Sp),
positive (PV+) and negative predictive values (PV-), posi-
tive (LR+) and negative likehood ratio (LR-). All non-P
falciparum infections were confirmed to be P. vivax by
microscopy and PCR (no detection of P. malariae and P.
ovale).
Ethical considerations
This study was approved by the Ethics Review Board of
the Universidad Peruana Cayetano Heredia, Lima, Peru
(Code SIDISI: 051675). Before any sample was taken, the
participants signed an informed consent.
Results
A total of 332 symptomatic malaria patients were
included in this study. The mean age was 32 ± 16 years.
The results of EM, PCR and Parascreen™ are shown in
Table 1. With EM, there were 234 negative and 98 posi-
tive slides, 83 P. vivax infections with parasite density
between 24 to 17,385 parasites/μl (2,662,323 ± 3,083.7)
and 15 P. falciparum infections with parasite density
between 36 to 36,457 parasites/μl (4,622.8 ± 8,920). With
PCR, there were 232 negative and 100 positive samples,
88 P. vivax, 11 P. falciparum and one mixed infection (P.
falciparum and P. vivax). With Parascreen™, there were
250 negative and 82 positive samples, 70 P. vivax infec-
tions and 12 P. falciparum.
EM was first compared to PCR as gold standard, show-
ing the following indicators: for detection of P. falciparum
malaria, Se: 90.9% and Sp: 96.8%; and for non-P. falci-
parum malaria, Se: 90.9% and Sp: 98.76%. A discrepancy
in species diagnosis between PCR and EM diagnosis was
observed in five cases (including one mixed infection
detected by PCR). Furthermore, four cases with negative
diagnosis by EM were detected positive by PCR, and two
cases with negative results by PCR tested positive by EM.
Table 2 presents the calculated indicators when
Parascreen™ was compared with EM and PCR. When EM
was used as gold standard, Parascreen™ had, for P. falci-
parum detection the following indicators: Se: 53.5%, Sp:
98.7%, PV+: 66.7%, PV-: 97.8%, LR+: 42.27 and LR-:0.47;
and for non-P. falciparum malaria Se: 77.1%, Sp: 97.6%,
PV+: 91.4%, PV-: 92.7%, LR+: 32.0 and LR-: 0.22. P. falci-
parum diagnosis using Parascreen™ had a high propor-
tion of false negatives 46.7% [95% CI (24.8-69.9)].
When PCR was used as gold standard, Parascreen™
showed a better sensitivity for detection of P. falciparum
and P. vivax infections. For P. falciparum, the indicators
were: Se: 81.8%, Sp: 99.1%, PV+: 75%, PV-: 99.4, LR+:
87.27 and LR-: 0.18. For non-P. falciparum the following
indicators were observed: Se: 76.1%, Sp: 99.2%, PV+:
97.1%, PV-: 92.0%, LR+: 92.51 and LR-: 0.24.
Parascreen™ had a low sensitivity (12.5%) for detection
of P. vivax infections at parasite densities below 99 para-
sites/μl, which increased for the detection of parasite
densities between 99 and 500 parasites/μl (sensitivity of
60%). For P. falciparum infections, parasite densities
below 1,000 parasites/μl were detected with less sensitiv-
ity (25%) than parasite densities > 1,000 parasites/μl (sen-
sitivity between 66.7% and 75.0%) (Table 3).
Table 1: Parascreen™ diagnosis results and comparison with diagnosis by PCR and EM.
Results by Parascreen™ PCR EM
Negative P.vivax P.falciparum Mixed Negative P.vivax P.falciparum
Negative 250 230 19 1 0 230 16 4
non-P. falciparum 70 16 7 1 136 4 3
P. falciparum 12 12 9 013 8
Total 332 232 88 11 1 234 83 15Bendezu et al. Malaria Journal 2010, 9:154
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Discussion
This study, conducted in Iquitos, Department of Loreto,
showed an unacceptable performance of Parascreen™ for
malaria diagnosis under the field conditions found in the
Peruvian Amazon. Even though the RDT was of simple
training and use for the local health staff, it showed vari-
a b l e  i n d i c a t o r s  w h e n  c o m p a r e d  w i t h  E M  a n d  P C R ,
depending on the Plasmodium species (P. vivax or P. fal-
ciparum) and parasitaemia of the infections.
In this study, Parascreen™ sensitivity for malaria infec-
tion was lower than the 100% sensitivity obtained in a
validity assessment done by Zephyr Biomedical System
[23]. In studies performed in Kenya [19] and India [21]
the sensitivity values were 94.0% and 96.3% respectively.
A study carried out in Ethiopia [20] describes similar
results to the ones obtained in this study. In comparison
with other RDTs, Parascreen™ sensitivity for P. falci-
parum infection was lower than that obtained with Opti-
MAL™ which detects Plasmodium  lactate
deshydrogenase. HRP2-based RDTs such as Parascreen™
have also been evaluated in various studies in South
American countries [25-28]. The sensitivity and specific-
ity for P. falciparum and P. vivax infections observed in
this study were better than those reported with AMRAD
fast test ICT P.f/P v in Peru [6], and similar to those
o b t a i n e d  w i t h  B i n a x  N O W ™  f a s t  t e s t  I C T  P.f/P.v  in
Table 2: Comparative indicators of Parascreen™, when using PCR and EM as gold standards.
gold standard Results by Parascreen™
Plasmodium
Species
Sensitivity
[%(95%CI)]a
Specificity
[%(95%CI)]
PPVb
[%(95%CI)]
PPNc
[%(95%CI)]
Likehood ratio
Positive test Negative test
EM non-P. falciparum 77.1
(67.0-84.4)
97.6
(94.8-98.9)
91.4
(82.5-96.0)
92.7
(89.0-95.3)
32 0.22
P. falciparum 53.5
(30.1-75.2)
98.7
(96.8-99.5)
66.7
(39.1-86.2)
97.8
(95.6-98.9)
42.27 0.47
PCR non-P. falciparum 76.1
(66.3-83.8)
99.2
(97.0-99.8)
97.1
(90.0-99.2)
92
(88.1-94.7)
92.51 0.24
P. falciparum 81.8
(52.3-94.9)
99.1
(97.3-99.7)
75
(46.8-91.1)
99.4
(97.7-99.8)
87.27 0.18
a.- Confidence interval at 95%.
b.- Positive predictive value.
c.- Negative predictive value.
Table 3: Parascreen™ sensitivity, PPV and False-negative proportion at different parasitaemia determined by expert microscopy.
Parascreen™ Parasite
density
(parasites/ul)
N
(Number of samples)
Sensitivity
[%(95%CI)]
PPV
[%(95%CI)]
False - negative
proportion
[%(95%CI)]
P. vivax
1-99 8 12.5 (2.2-47.1) 100 87.5 (52.9-97.8)
100-499 15 60.0 (35.7-80.2) 100 40.0 (19.8-64.3)
500-999 13 84.6 (57.8-95.7) 100 15.4 (4.3-42.2)
1,000-4,999 35 91.4 (77.6-97.0) 100 8.6 (3.0-22.4)
+ 5,000 12 91.7 (64.6-98.5) 100 8.3 (1.5-35.4)
P. falciparum
1-999 5 25.0 (4.6-69.9) 100 75.0 (30.1-95.4)
1,000-1,999 3 66.7 (20.8-93.9) 100 33.3 (6.1-79.2)
2,000-4,999 4 75.0 (30.1-95.4) 100 25.0 (4.6-69.9)
+ 5,000 3 66.7 (20.8-93.9) 100 33.3 (6.1-79.2)
a,b.- Abbreviations as in Table 2Bendezu et al. Malaria Journal 2010, 9:154
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Colombia, but lower than those observed with NOW-
Malaria-ICT RDT in an evaluation study in Colombia
[18] and in various other studies of OptiMAL IT
[6,10,11,13,26].
The likelihood ratio (Lr) is independent of the preva-
lence of the disease in the population, and can be used to
determine the accuracy of positive or negative test results
[29]. In this study, high likelihood ratios of a positive test
(Lr+), above 10, were found for P. falciparum and non-P.
falciparum infections; confirming that patients with posi-
tive tests would have a high probability to be infected.
O n  t h e  c o n t r a ry ,  t h e  o b s e r v e d  l i k e l i h o o d  r a t i o s  o f  a
n e g a t i v e  P a r a s c r e e n ™  t e s t  ( L r - ) ,  w i t h  v a l u e s  a b o v e  0 . 1 ,
indicated a high risk of error when excluding malaria
diagnosis in patients with negative tests. Similar findings
were found in an evaluation study of OptiMAL™ in febrile
travelers returning from malaria endemic countries,
especially with P. falciparum infections [30].
More generally, it should be noted that PCR could be
more relevant as a reference method for the evaluation of
non-microscope procedures like RDTs [8,14,31], but the
indicators still need to be considered with reference to
EM, for inter-study comparisons.
RDTs generally achieve a sensitivity of > 90% at densi-
ties above 100 parasites per μL of blood, and the sensitiv-
ity decreases markedly below that level of parasite
density.
The low number of P. falciparum infections in this
study could explain the low Parascreen™ sensitivity for P.
falciparum infections, as well as the sensitivity discrepan-
cies when using EM and/or PCR as gold standards. Other
possible factors, could consist in the genetic diversity of
the parasite antigen HRP-2 [32], the existence of parasites
that do not carry the pfhrp2 gene in this region [17,33]
and the lack of monoclonal antibodies specificity used by
the RDT to detect the HRP- 2 antigen [34]. When this
study was carried out in 2006, and this RDT chosen for
validation, the existence of P. falciparum isolates lacking
the  pfhrp2  gene in this region was still unknown and
unpredictable, but now this recent discovery has to be
taken into account when interpreting results of RDT eval-
uation studies in general.
Conclusions
The present study showed that Parascreen™ sensitivity
was comparable to EM and PCR at parasitaemia levels
≥100 parasites/μl in P. vivax infections and ≥1,000 para-
sites/μl for P. falciparum infections. In general,
Parascreen™ sensitivity was low for Plasmodium  infec-
tions, especially for fatal infections like P. falciparum.
This RDT was not acceptable for malaria diagnosis under
the field conditions found in the Peruvian Amazon, even
though it was easy to learn and to use by the local health
staff. The choice of a RDT for Amazonian countries such
as Peru, should consider the local malaria incidence and
predominance of Plasmodium  s p e c i e s ,  a s  w e l l  a s  t h e
genetic characteristics of the parasites, especially the
existence in this region of P. falciparum field isolates lack-
ing the pfhrp2 gene.
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